Consistent with this, an additional analysis of the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS) trial in 10,061 patients showed that the administration of canakinumab (a monoclonal antibody against IL-1β) dose-dependently reduced the incidence of lung cancer and lung cancer mortality (phase III, NCT01327846) [135]. Here, IL1B is linked to lung cancer.